Profil
Paul Rivard is currently the VP-Operations & General Counsel at MyMD Pharmaceuticals (Florida), Inc. Previously, he held the position of President & General Counsel at MIRA Pharmaceuticals, Inc. He also served as the Chief Legal Officer & Vice President-Operations at TNF Pharmaceuticals, Inc. from 2021 to 2023.
Mr. Rivard completed his undergraduate degree at Clarkson University in 1992 and obtained his graduate degree from Columbus School of Law in 1998.
Aktive Positionen von Paul Rivard
| Unternehmen | Position | Beginn |
|---|---|---|
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Geschäftsführer | - |
Ehemalige bekannte Positionen von Paul Rivard
| Unternehmen | Position | Ende |
|---|---|---|
| Q/C TECHNOLOGIES, INC. | Geschäftsführer | 14.11.2023 |
| MIRA PHARMACEUTICALS, INC. | Präsident | - |
Ausbildung von Paul Rivard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Clarkson University
Clarkson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbus School of Law
Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Health Technology |
MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan | Health Technology |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
















